Arctic Bioscience AS is a public limited company, incorporated in accordance with Norwegian law. Arctic Bioscience was listed on Euronext Growth, Oslo on 24 February 2021, under the ticker ABS-ME.
Arctic Bioscience is a biotech company developing unique pharmaceutical and nutraceutical products based on bioactive marine compounds. The company is developing a novel, cost-efficient oral treatment for mild-to-moderate psoriasis – a large global market with significant unmet medical need. Nutraceutical products are sold globally both B2C and B2B under the brand name ROMEGA™. Our story and growth potential is not only reflected in our current business figures but also the latest developments on the stock market.
Get the latest news and stock exchange notifications from Arctic Bioscience by subscribing to our newsletter.
If you change your mind you can unsubscribe by following the link in the footer of any e-mail you receive from us. We will then delete your e-mail address from our register.